You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
HQL-79 is a selective inhibitor of PGD (hematopoietic prostaglandin D) synthase (PGE synthase). It is a synthetic tetrazole compound originally prepared as a possible antihistamine. Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 inhibits the synthesis of PGD2. HQL-79 is thus a likely lead compound for the preparation of potent, selective PGE synthase inhibitors.
1. Matsushita, N., et al., 1998. Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models. Japanese journal of pharmacology. 78(1): 1-10. PMID: 9804056
2. Matsushita, N., et al., 1998. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Japanese journal of pharmacology. 78(1): 11-22. PMID: 9804057
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.